计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| V413811-100mg |
100mg |
现货 ![]() |
| |
| V413811-250mg |
250mg |
现货 ![]() |
| |
| V413811-1g |
1g |
现货 ![]() |
| |
| V413811-5g |
5g |
期货 ![]() |
|
| 英文别名 | Sacubitril mixture with Valsartan | Valsartan | Sacubitril | LCZ696 |
|---|---|
| 规格或纯度 | ≥99% |
| 英文名称 | Sacubitril/valsartan (LCZ696) |
| 生化机理 | 萨库比特利/缬沙坦(LCZ696,Sacubitril,Valsartan)由摩尔比为 1:1 的缬沙坦和萨库比特利组成,是一种口服生物利用型双效血管紧张素受体-肾素抑制剂(ARNi),用于治疗高血压和心力衰竭。第 3 阶段 |
| 储存温度 | 避光,-20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
Sacubitril/Valsartan (LCZ696) 是由 Valsartan (an ARB) 和 Sacubitril (AHU377) 组成,摩尔比为 1:1,是一种首创的血管紧张素受体-脑啡肽酶 (ARN) 双抑制剂,用于研究高血压和心力衰竭。它可通过抑制炎症、氧化应激和细胞凋亡来改善糖尿性心肌病 Information Sacubitril/valsartan (LCZ696) Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3. Targets RAAS In vivo In double-transgenic rats overexpressing human renin and angiotensinogen and plasma atrial natriuretic peptide immunoreactivity, LCZ696 (60 mg/kg p.o.) induces a dose-dependent and long-lasting reduction in mean arterial pressure (MAP), and stimulates a rapid and dose-dependent augmentation of plasma ANP immunoreactivity. In rat myocardial infarction (MI) model, LCZ696 (68 mg/kg p.o.) attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. |
| 纯度 | ≥99% |
| 分子量 | 915.98 |
|---|
| 溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL warmed with 50ºC Water: bath (109.17 mM); Water: 100 mg/mL warmed with 50ºC Water: bath (109.17 mM); Ethanol: 100 mg/mL warmed with 50ºC Water: bath (109.17 mM); |
|---|---|
| 敏感性 | 对光线敏感;对湿度敏感 |
¥1,039.92